Despite some health benefits, could cannabis break your heart?
While marijuana is becoming more available nationwide as medicine and for recreational use, two new studies build on growing evidence that cannabis users are more apt to have heart attacks than those who do not use the drug. And it's true even among young, healthy adults.
Cannabis users who are not yet 50 are six times as likely to have heart attacks as those who don't use the drug, per a retrospective study involving 4.6 million people that was published in JACC Advances, one of the American College of Cardiology's journals. And a review of 12 previous studies — the largest to look at the issue of heart attacks and cannabis use — found 50% increased risk among cannabis users.
The findings are being presented at the American College of Cardiology's Annual Scientific Session next week in Chicago.
UPI.com reported that marijuana is legal for recreational use in 24 states and for medical use in 39 states.
'Asking about cannabis use should be part of clinicians' workup to understand patients' overall cardiovascular risk, similar to asking about smoking cigarettes,' said Dr. Ibrahim Kamel, clinical instructor at the Boston University Chobanian & Avedisian School of Medicine and internal medicine resident at St. Elizabeth Medical Center in Boston, who led the study. 'At a policy level, a fair warning should be made so that the people who are consuming cannabis know that there are risks.'
The retrospective study took data from TriNetX, a global health research network that lets researchers use electronic medical records. Over follow-up averaging more than three years, the researchers found that cannabis users had:
More than a sixfold increased risk of heart attack
Fourfold increased risk of ischemic stroke
Twofold increased risk of heart failure
Threefold increased risk of cardiovascular death, heart attack or stroke
Those participants were all younger than 50 and didn't have any significant cardiovascular problems when the study began, 'with blood pressure and low-density lipoprotein (LDL) cholesterol levels within a healthy range and no diabetes, tobacco use or prior coronary artery disease,' according to a news release on the study.
In the other study, which reviewed an international collection of previous research involving more than 75 million people, mostly conducted in the U.S., seven found a link between cannabis use and having a heart attack, four didn't, and one suggested less risk. When all the study data was pooled, a link between cannabis use and heart attack was significant. Users were 1.5 times as apt to have a heart attack compared to those not currently using.
Not all of those studies included age, but among those that did, 41 years old was average, suggesting 'a relatively young population,' the researchers said.
Dr. Sameer Amin, cardiologist and chief medical officer at L.A. Care Health Plan, who was not part of the research, told Healthline that more research is needed. But 'based on early information showing an association of cannabis with an increased risk of worse cardiovascular outcomes, there appears to be an emerging concern.'
Why cannabis might increase risk of heart attack isn't known, the researchers theorize it could impact heart rhythm, increase oxygen demand in the heart and make it harder for blood vessels to relax and expand, thus changing blood flow. The release noted that one study found the risk of heart attack peaked an hour after marijuana consumption.
Because of the data, the researchers couldn't eliminate the possibility of confounders that could also influence the results, such as the amount and duration of cannabis use or use of tobacco and other drugs.
'We should have some caution in interpreting the findings in that cannabis consumption is usually associated with other substances such as cocaine or other illicit drugs that are not accounted for,' Kamel said. 'Patients should be forthcoming with their doctors and remember that we are their No. 1 advocate and having the full story matters.'
The researchers said they're hoping to do more studies on the issue. They note an earlier study presented at the American College of Cardiology's Annual Scientific Session in 2023 found daily marijuana use increased risk of developing coronary artery disease.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 days ago
- Medscape
Diabetes Status May Not Affect Outcomes of Preventive PCI
The PREVENT trial found preventive percutaneous coronary intervention (PCI) combined with optimal medical therapy was more effective than medical therapy alone in reducing major adverse cardiac events in patients with non–flow-limiting vulnerable plaques. The new analysis found patients with non–flow-limiting vulnerable plaques had similar 2-year cardiac outcomes regardless of diabetes status, but those who received preventive PCI combined with optimal medical therapy had lower rates of cardiac events than those who received medical therapy alone. METHODOLOGY: The post hoc analysis of the PREVENT data compared the clinical outcomes of preventive PCI plus optimal medical therapy and medical therapy alone in patients with (n = 490) or without (n = 1116) diabetes. Plaques were defined as non–flow-limiting when the fractional flow reserve was > 0.80; vulnerable plaques were identified using intracoronary imaging. The primary endpoint was a composite of cardiac death, target vessel myocardial infarction, ischemia-driven target vessel revascularization, or hospitalization for unstable or progressive angina at 2 years after randomization; the median follow-up duration was 4.3 years. TAKEAWAY: At 2 years, the incidence of the composite primary endpoint was not significantly different between patients with diabetes and those without the condition (1.8% and 1.9%, respectively; P = .956). = .956). The composite primary endpoint occurred less frequently with preventive PCI than with optimal medical therapy alone for both patients with diabetes (0% vs 3.7%; log-rank P = .003) and those without diabetes (0.5% vs 3.2%; log-rank P < .001). = .003) and those without diabetes (0.5% vs 3.2%; log-rank < .001). The reduced incidence of the primary endpoint with preventive PCI was mainly driven by reduced rates of ischemia-driven target vessel revascularization and hospitalizations for unstable or progressive angina in both patients with diabetes and those without the disorder. IN PRACTICE: 'These findings support that preventive PCI…irrespective of diabetes status, in patients with non–flow-limiting vulnerable coronary plaques,' the researchers wrote. Vulnerable plaques 'may be guilty by association but may not be the sole culprit behind residual cardiovascular risk,' wrote Diana A. Gorog, MD, PhD, of Imperial College London, London, England, in an editorial accompanying the journal article. Such plaques 'may be just one marker of a vulnerable patient, but not the only determinant of risk. Perhaps we need to find better ways of identifying the vulnerable patient, rather than focusing solely on vulnerable plaques,' Gorog added. SOURCE: This study was led by Min Chul Kim of Chonnam National University Hospital in Gwangju, South Korea. It was originally presented at American College of Cardiology (ACC) Scientific Session 2024 and was published online on May 29, 2025, in European Heart Journal . LIMITATIONS: The clinical outcomes were exploratory as the study was powered only for the composite primary endpoint, with event rates lower than anticipated. The researchers did not differentiate between type 1 and type 2 diabetes, which might have limited the generalizability of the findings. Intravascular imaging at follow-up was not performed routinely. DISCLOSURES: This study was funded by the CardioVascular Research Foundation, Abbott, Yuhan Corp, CAH-Cordis, Philips, and Infraredx. Several authors reported receiving research grants, consulting fees, and honoraria from various pharmaceutical and healthcare companies, including the funding agencies.
Medscape
7 days ago
- Medscape
Same-Day Discharge Criteria Outlined for AF Ablation
SAN DIEGO — Same-day discharge after ablation of atrial fibrillation (AF) is an appropriate strategy for saving costs if performed with strict selection criteria and protocols, according to a recently issued joint statement from the American College of Cardiology and the Heart Rhythm Society. Same-day discharge has long been indicated for catheter ablations to abort routine atrial flutter, atrioventricular nodal reentrant tachycardia, and focal atrial tachycardias, according to the authors of the new joint statement. Although they maintained patients selected for elective catheter ablation of AF require heightened scrutiny, they endorsed same-day AF ablation when used selectively. The statement evaluates 'evidence supporting shorter hospitalization stay with same-day discharge for intracardiac ablations agonistic to site of care,' reported Amit J. Shankar, MD , an electrophysiologist with Canton-Potsdam Hospital in Potsdam, New York, who served as a representative for the Heart Rhythm Society in developing the statement. Whether in a hospital setting or an outpatient facility, the statement describes same-day discharge ablation as an opportunity to improve patient access, improve efficiency, and reduce healthcare costs. The adoption of same-day discharge after AF ablation was accelerated during the COVID-19 pandemic, said Samuel O. Jones, MD, a cardiologist affiliated with The Chattanooga Heart Institute in Chattanooga, Tennessee, and a fellow of the American College of Cardiology. 'Improved workflows, technological innovations, and procedure advancements have also contributed to the high rates at which these are performed,' added Jones, who helped write the statement. The statement was released on April 24 to coincide with the first day of the Heart Rhythm Society (HRS) 2025 annual scientific meeting. It was simultaneously published in Heart Rhythm and the Journal of the American College of Cardiology . The scientific statement's recommendation is intended for elective rather than urgent or emergency ablations. Support for the statement was drawn from multiple case-controlled studies, meta-analyses, and outcome databases. In one example, a 12-study meta-analysis with data from more than 18,000 elective ablations showed no significant differences in major complications from the procedure among the 40.5% of patients discharged the same day relative to those who were discharged after at least one night in the hospital. In another study, drawn from a real-world prospective registry, outcomes were compared for potential candidates for same-day ablation on the basis of prespecified criteria and those who were not eligible for the procedure. These criteria included no bleeding history, a left ventricular ejection fraction greater than 40%, no pulmonary disease, and no surgical procedures within the previous 60 days. Of the 2332 patients included in the analysis, 1982 (85%) were deemed candidates for same-day ablation. Although freedom for atrial arrhythmias was comparable ( P = .0212) for the two groups, patients discharged the same day had a lower rate of complications (0.8% vs 2.9%; P < .001). The rate of readmission was similar (0.8% vs 09%; P = .924), according to the researchers. Contraindications for Same-Day Ablation In the document, relative contraindications for same-day ablation include decompensated heart failure, significant pulmonary disease, significant risk of bleeding, and any major unstable comorbidities such as diabetes, hypertension, or renal disease. The document recommends limiting same-day procedures to patients who can have readily available social support and can return to a hospital quickly in the event of a post-procedural complication. Acknowledging that most large hospitals offering ablation for AF already have formal selection criteria and protocols in place for same-day discharge, the authors called for free-standing sites to establish their own if they have not done so. In these settings, the authors emphasized the need to rigorously follow prespecified and 'ironclad' selection criteria and protocols. From this standpoint, Shankar said same-day procedures should always be performed on the basis of shared decision-making with the patient. While the economic benefits of same-day procedures might be shared by the facility and the patient, the latter should understand the inherent differences in the settings and participate actively in any decision of where the ablation is performed. Jones said while a substantial body of evidence supports same-day AF ablation as a safe and effective procedure that can free up necessary resources in the healthcare facility, the potential advantages are relevant only to appropriately selected patients. The new statement also suggests transfer agreements with inpatient facilities should be arranged in advance and that patients should be informed such a transfer is a possibility outside of a hospital setting. However, the document makes clear same-day ablations in alternative sites of care are reasonable when the precautions are observed. In any setting that AF ablation is performed, the writing committee encouraged tracking outcomes to ensure that high-quality care is achieved and sustained. Shankar and Jones reported no potential conflicts of interest.
Yahoo
12-05-2025
- Yahoo
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. 'We are pleased to have recently announced positive topline results from our pivotal trials, Launch-HTN and Advance-HTN, that evaluated lorundrostat's efficacy and safety as a potential treatment for patients with uncontrolled or resistant hypertension. The Advance-HTN late-breaking presentation at the American College of Cardiology meeting and the recent publication in the New England Journal of Medicine underscore the strength of our clinical data and the potentially transformative nature of lorundrostat. With the success of our two pivotal trials, we are working toward submitting our new drug application with a pre-NDA meeting with the FDA anticipated in the fourth quarter of 2025,' stated Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. 'We are excited to announce the appointment of Eric Warren as our Chief Commercial Officer. Eric's proven leadership skills, extensive cardiovascular experience and track record of success, will be invaluable to Mineralys as we solidify our commercial and partnering strategy.' Recent Clinical Highlights and Upcoming Milestones Pivotal Launch-HTN Phase 3 Trial – The trial met its primary endpoint in evaluating the efficacy and safety of lorundrostat for the treatment of subjects with uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) as add-on therapy, who fail to achieve blood pressure control on their existing medications. The trial reported that the lorundrostat 50 mg dose achieved a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001), as assessed by automated office blood pressure at week six. This benefit was sustained with potential further reduction through week 12, with a 19.0 mmHg reduction in automated office systolic blood pressure and an 11.7 mmHg placebo-adjusted reduction (p-value <0.0001). The clinical safety results, including adrenocorticotropic hormone (ACTH)-stimulated and serum cortisol, change in serum potassium, serum sodium, and estimated glomerular filtration rate (eGFR), as well as incidence of hypotension, from the trial support a favorable benefit-risk profile in a 'real world' setting. The incidence of hyperkalemia (serum potassium >6.0 mmol/L) at the scheduled study visit was 1.1% and 1.5% in the 50 mg and 50 to 100 mg arms, respectively. After exclusion of factitious test results, the incidence of confirmed hyperkalemia was 0.6% and 1.1%, respectively. The Launch-HTN trial has been accepted as a late-breaking presentation at the 2025 European Society of Hypertension Meeting on Hypertension and Cardiovascular Protection, which is being held in Milan, Italy on May 23-26, 2025. Pivotal Advance-HTN Trial – Detailed results from the Advance-HTN trial were recently presented in a late-breaking presentation at the American College of Cardiology's ACC.25 meeting and published on May 8th in the New England Journal of Medicine. The trial met its primary endpoints in evaluating the efficacy and safety of lorundrostat for the treatment of confirmed uHTN or rHTN. The trial reported that the lorundrostat 50 mg dose cohort achieved a 15.4 mmHg absolute reduction in systolic blood pressure and a 7.9 mmHg placebo-adjusted reduction (p-value = 0.001), as assessed by 24-hour ambulatory blood pressure monitoring at 12 weeks. Lorundrostat demonstrated a favorable safety and tolerability profile, with modest changes in serum potassium, serum sodium and eGFR, and a low discontinuation rate. The incidence of hyperkalemia (serum potassium >6.0 mmol/L) at the scheduled study visit was 5.3% and 7.4% in the 50 mg and 50 to 100 mg arms, respectively. After exclusion of factitious test results, the incidence of confirmed hyperkalemia was 2.1% and 3.2%, respectively. These results reinforce lorundrostat's favorable benefit-risk profile in a high-risk population that would typically be treated by specialists rather than general practitioners. Transform-HTN Open-Label Extension Trial – The Company's ongoing open-label extension trial allows subjects to continue to receive lorundrostat and the Company to obtain additional safety and efficacy data. Explore-CKD Phase 2 Trial – Enrollment has been completed and topline data are anticipated in the second quarter of 2025. The trial is designed to evaluate the safety and efficacy of lorundrostat when added to background treatment with an ACE inhibitor or ARB and a SGLT2 inhibitor for the treatment of hypertension in subjects with Stage 2 to 3b CKD (eGFR greater than or equal to 30 mL/min/1.73m2 ) and albuminuria. Explore-OSA Phase 2 Trial – The Company initiated the trial in the first quarter of 2025, which will evaluate the safety and efficacy of lorundrostat in the treatment of overweight and obese subjects with moderate-to-severe OSA and hypertension. Expanded Management Team – Appointed Eric Warren as Chief Commercial Officer. Mr. Warren brings more than three decades of commercial leadership experience across multiple healthcare segments with a heavy emphasis on cardiovascular disease. Mr. Warren will lead the Company's commercial strategy and support future partnering opportunities. Strengthened Balance Sheet – On March 18, 2025, the Company completed a public equity financing for gross proceeds of approximately $201.2 million, before deducting fees and expenses. The Company reported a total of $343.0 million of cash, cash equivalents and investments as of March 31, 2025. First Quarter 2025 Financial Highlights Cash, cash equivalents and investments were $343.0 million as of March 31, 2025, compared to $198.2 million as of December 31, 2024. The Company believes that its current cash, cash equivalents and investments will be sufficient to fund its planned clinical trials and regulatory activities, as well as support corporate operations, into 2027. Research and Development (R&D) expenses for the quarter ended March 31, 2025 were $37.9 million, compared to $30.8 million for the quarter ended March 31, 2024. The increase in R&D expenses was primarily due to increases of $4.8 million in preclinical and clinical costs and $2.8 million in compensation expense resulting from additions to headcount, increases in salaries and accrued bonuses and increased stock-based compensation, partially offset by $0.5 million in lower clinical supply, manufacturing and regulatory costs. General and Administrative (G&A) expenses were $6.6 million for the quarter ended March 31, 2025, compared to $4.6 million for the quarter ended March 31, 2024. The increase in G&A expenses was primarily due to $1.2 million in higher compensation expense resulting from additions to headcount, increases in salaries and accrued bonuses and increased stock-based compensation, and $0.7 million in higher professional fees. Total other income, net was $2.2 million for the quarter ended March 31, 2025, compared to $3.9 million for the quarter ended March 31, 2024. The decrease was primarily attributable to decreased interest earned on our investments in money market funds and U.S. treasuries. Net loss was $42.2 million for the quarter ended March 31, 2025, compared to $31.5 million for the quarter ended March 31, 2024. The increase was primarily attributable to the factors impacting the Company's expenses described above. Conference Call The Company's management team will host a conference call at 4:30 p.m. ET on Monday, May 12, 2025. To access the call, please dial 1-800-717-1738 in the United States or 1-646-307-1865 outside the United States. A live webcast of the conference call may be found here. A replay of the call will be available on the 'News & Events' page in the Investor Relations section of the Mineralys Therapeutics website (click here). About Hypertension Having sustained, elevated blood pressure (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the United States. In 2022, more than 685,000 deaths in the United States included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an average annual economic burden of about $219 billion in the United States in 2019. Less than 50% of hypertension patients achieve their blood pressure goal with currently available medications. Dysregulated aldosterone levels are a key factor in driving hypertension in approximately 30% of all hypertensive patients. About CKD CKD, which is characterized by the gradual loss of kidney function, is estimated to affect more than 10% of the global population and is one of the leading causes of mortality worldwide. According to the U.S. Centers for Disease Control and Prevention (CDC), an estimated 1-in-7 (15%) of U.S. adults have CKD. Diabetes and hypertension are responsible for approximately two-thirds of CKD cases. Early detection and treatment can often keep CKD from getting worse. When CKD progresses, it may eventually lead to kidney failure, which requires dialysis or a kidney transplant to maintain life. About OSA OSA is characterized by repetitive overnight hypoxic episodes and subsequent sleep fragmentation due to a complete or partial collapse of the upper airway. Moderate OSA is defined as having between 15 and 30 breathing pauses (apnea or hypopnea events) per hour of sleep, while severe OSA indicates more than 30 breathing pauses per hour. OSA impacts almost one billion people globally, including 425 million moderate-to-severe cases. Around 80% of adults with OSA are undiagnosed. As of 2015, undiagnosed OSA is estimated to cost the United States approximately $149.6 billion annually from comorbid disease, workplace accidents, motor vehicle accidents and loss of workplace productivity. Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with rHTN. Additionally, untreated moderate-to-severe OSA increases the risk of rHTN. Along with hypertension, OSA is a major risk factor of cardiovascular disease, type-2 diabetes mellitus and stroke. About Lorundrostat Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uHTN or rHTN, as well as CKD and OSA. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in hypertensive subjects. In a Phase 2, proof-of-concept trial (Target-HTN) in uncontrolled or resistant hypertensive subjects, once-daily lorundrostat demonstrated statistically significant and clinically meaningful systolic blood pressure reduction in both automated office systolic blood pressure measurement and 24-hour ambulatory systolic blood pressure monitoring. Adverse events observed were a modest increase in serum potassium, decrease in eGFR, urinary tract infection and hypertension, with one serious adverse event possibly related to study drug being hyponatremia. About Mineralys Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit Follow Mineralys on LinkedIn and Twitter. Forward-Looking Statements Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the Company's expectation that aldosterone synthase inhibitors with an SGLT2 inhibitor may provide additive clinical benefits to patients; the Company's expectation that Advance-HTN and Launch-HTN may serve as pivotal trials in any submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA); the Company's ability to evaluate lorundrostat as a potential treatment for CKD, OSA, uHTN or rHTN; the planned future clinical development of lorundrostat and the timing thereof; and the expected timing of commencement and enrollment of patients in clinical trials and topline results from clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: topline results that we report are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial; our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; later developments with the FDA may be inconsistent with the feedback from the completed end of Phase 2 meeting, including whether the proposed pivotal program will support registration of lorundrostat which is a review issue with the FDA upon submission of an NDA; the results of our clinical trials, including the Advance-HTN and Launch-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for an NDA submission or regulatory approval of lorundrostat; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs, and the potential for a local and/or global economic recession; our ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Mitsubishi Tanabe Pharma to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading 'Risk Factors' in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact:Investor Relationsinvestorrelations@ Media RelationsTom WeibleElixir Health Public RelationsPhone: (1) 515-707-9678Email: tweible@ Mineralys Therapeutics, Inc. Condensed Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended March 31, 2025 2024 Operating expenses: Research and development $ 37,879 $ 30,754 General and administrative 6,568 4,608 Total operating expenses 44,447 35,362 Loss from operations (44,447 ) (35,362 ) Interest income, net 2,239 3,853 Other income (expense) (3 ) 1 Total other income, net 2,236 3,854 Net loss $ (42,211 ) $ (31,508 ) Net loss per share attributable to common stockholders, basic and diluted $ (0.79 ) $ (0.70 ) Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted 53,163,551 44,900,755 Mineralys Therapeutics, Inc. Selected Financial Information Condensed Balance Sheet Data (amounts in thousands) (unaudited) March 31, December 31, 2025 2024 Cash, cash equivalents and investments $ 343,026 $ 198,187 Total assets $ 354,941 $ 205,903 Total liabilities $ 13,386 $ 14,646 Total stockholders' equity $ 341,555 $ 191,257
